Anti-human igm monoclonal antibody, its hybridoma cell line and application

A technology of hybridoma cell lines and monoclonal antibodies, which is applied in the fields of instruments, peptides, immunoglobulins, etc., can solve the problem of systematic evaluation of cross-reactivity, stability, detection sensitivity and specificity, and whether antibodies are suitable for preparation Problems such as unclear in vitro diagnostic reagents and low specificity of polyclonal antibodies have been achieved to achieve excellent long-term and thermal stability, good immune effect, loose storage conditions and operating conditions

Active Publication Date: 2019-10-18
SICHUAN ANKERUI NEW MATERIAL TECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In recent years, there have been some studies on anti-human IgM monoclonal antibodies. For example, a patent document WO2010026758A1 discloses an anti-human IgM monoclonal antibody. This patent aims to solve the problem of low specificity of polyclonal antibodies, and focuses on the study of The properties of cloning antibodies to induce agglutination between human IgM and verifying their effect of inhibiting non-specific reactions, but did not pay attention to the systematic evaluation of this anti-human IgM monoclonal antibody when used in in vitro diagnostic reagents (eg, antibody titer, Cross-reactivity, stability, detection sensitivity and specificity, etc.), therefore, whether the antibody is suitable for the preparation of in vitro diagnostic reagents is not clear
[0005] Another example is the anti-human IgM monoclonal antibody of Xiamen Bosheng Biotechnology Co., Ltd., which is a common commercial anti-human IgM monoclonal antibody, but its stability is not good enough, so it is insufficient when used in immunodiagnostic antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-human igm monoclonal antibody, its hybridoma cell line and application
  • Anti-human igm monoclonal antibody, its hybridoma cell line and application
  • Anti-human igm monoclonal antibody, its hybridoma cell line and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] The immunization of embodiment 1 mice

[0066] Human IgM extracted from blood (Sichuan Mike Bio-New Material Technology Co., Ltd., batch number 150127) was diluted to 3.0 mg / ml with normal saline, mixed with an equal volume of Freund's complete adjuvant (Sigma Company, product number SLBF-9338V), and used A 1ml syringe was emulsified into an oily emulsion until the oily emulsion dripped into water did not disperse and then the emulsification could be stopped. The emulsion was subcutaneously administered to BALB / c mice in the armpits of limbs at a dose of 150 μl / only (Chengdu Dashuo Experimental Animal Center, 6 weeks) 21 days after the first immunization, human IgM was mixed with incomplete Freund's adjuvant (Sigma Company, product number SLBM9367V) in equal volumes and then emulsified. The immunization dose was 75 μl / cause, and boosted every other week thereafter. After immunization once, the tail blood was collected before each immunization, the serum was separated, a...

Embodiment 2

[0067] The preparation of embodiment 2 hybridoma cell lines

[0068] 2-1 Preparation of feeder cells

[0069] Peritoneal macrophages of normal 10-week-old BALB / c mice were used as feeder cells. One day before the fusion, BALB / c was killed by taking blood from the eyes, soaking in 0.1% bromogeramine for 1 minute, then soaking in 75% alcohol for 1 minute, and cutting the abdominal skin with scissors under aseptic operation in the ultra-clean bench to expose the peritoneum. Inject 5ml of RPMI1640 basal culture solution into the peritoneal cavity with a syringe, then take it out with a dropper, then add 5ml of RPMI1640 basal culture solution to wash repeatedly, recover the washing solution, centrifuge at 1000rpm for 5 minutes, and use RPMI1640 culture solution that has been added with 20% newborn bovine serum Resuspend, adjust cell concentration to 2.9×10 5 cells / ml, added to 96-well plate, 100 μl / well, 37°C, 5% CO 2 nourish.

[0070] 2-2 Preparation of immune splenocytes

[...

Embodiment 3

[0080] The preparation of embodiment 3 monoclonal antibody

[0081] Select 6-8 weeks healthy BALB / c mice, inject 0.5ml liquid paraffin (Tianjin Kemiou) into each mouse intraperitoneally, and inject 1.5×10 6 a hybridoma cell. Ascites can be produced 7 to 10 days after inoculation of the cells. Closely observe the health status and signs of ascites of the animals. When ascites is as large as possible, and before the mice are about to die, the mice are killed, and the ascites is sucked into the test tube with a dropper. One mouse 1 ~ 5ml ascites can be obtained. The collected ascites was centrifuged to obtain the supernatant, and a small sample was taken and stored in a -20°C refrigerator. The ascitic fluid was saturated and precipitated with ammonium sulfate, and then purified with protein A affinity chromatography, and the purity of the antibody was greater than 90% as detected by SDS-PAGE. (denoted as IgM-Ab4), the electrophoresis results are as follows figure 1 shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can be specifically bound with human IgM, and can be used for in-vitro detection of the human IgM, and especially suitable for the early diagnosis of toxoplasma infection. The invention further relates to a kit containing the hybridoma cell strains or the monoclonal antibodies.

Description

technical field [0001] The present invention relates to a monoclonal antibody, in particular to an anti-human IgM monoclonal antibody. Background technique [0002] Immunodiagnostic reagents are one of the main types of in vitro diagnostic reagents. It utilizes the specific reaction of the combination of antigen and antibody to perform qualitative or quantitative diagnosis. Whether it is technology or market, this type of reagent is the fastest growing among all diagnostic reagent products at present. [0003] After pathogenic microorganisms infect the human body, IgM antibodies are first produced during the stimulation-induced humoral immune response. Early diagnosis of infectious diseases is the prerequisite for early and effective treatment, especially for infectious diseases with acute onset and dangerous conditions. , early diagnosis is particularly important, because the first antibody that appears in the body after infection is IgM antibody, so the detection of speci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/20C07K16/42G01N33/577G01N33/68
Inventor 黄家菊王磊舒川李岚敏何涛龙腾镶
Owner SICHUAN ANKERUI NEW MATERIAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap